ID

44014

Descrizione

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00477581

collegamento

https://clinicaltrials.gov/show/NCT00477581

Keywords

versioni (2)
  1. 05/09/17 05/09/17 -
  2. 20/09/21 20/09/21 -
Caricato su

20 settembre 2021

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes Mellitus NCT00477581

Inglese

Eligibility Type 2 Diabetes Mellitus NCT00477581

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment with metformin for at least 2 months
Descrizione

Metformin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0025598
has hba1c 7.0% to 11.0%, inclusive, at screening
Descrizione

Glycosylated hemoglobin A

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi)25 kg/m^2 to 45 kg/m^2, inclusive
Descrizione

Body mass index

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1305855
list of medications that are not allowed or the patient has been on stable treatment for at least 2 months:
Descrizione

Pharmaceutical Preparations Illicit | Therapeutic procedure Stable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332266
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0205360
hormone replacement therapy (female subjects)
Descrizione

Hormone replacement therapy | Gender

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0282402
UMLS CUI [2]
C0079399
oral contraceptives (female subjects)
Descrizione

Gender Oral Contraceptives

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0009905
antihypertensive agents
Descrizione

Antihypertensive Agents

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003364
lipid-lowering agents
Descrizione

Antilipemic agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0086440
thyroid replacement therapy
Descrizione

Thyroid hormone replacement therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2242640
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
has been treated with exenatide (byetta®) or any dpp-4 inhibitor prior to screening
Descrizione

Exenatide | Byetta | Dipeptidyl-Peptidase IV Inhibitors

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0167117
UMLS CUI [2]
C1636686
UMLS CUI [3]
C1827106
received any study medication or participated in any type of clinical trial within 30 days prior to screening
Descrizione

Investigational New Drugs | Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2348568
has donated blood within 60 days of screening visit or is planning to donate blood during the study
Descrizione

Blood Donation | Blood Donation Planned

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005794
UMLS CUI [2,1]
C0005794
UMLS CUI [2,2]
C1301732
treated with any of the following medications:
Descrizione

Pharmaceutical Preparations

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013227
sulfonylurea or thiazolidinedione within 3 months of screening;
Descrizione

Sulfonylurea | Thiazolidinediones

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038766
UMLS CUI [2]
C1257987
alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (symlin®)within 30 days of screening;
Descrizione

alpha-Glucosidase Inhibitors | Meglitinide | nateglinide | Pramlintide | Symlin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1299007
UMLS CUI [2]
C0065880
UMLS CUI [3]
C0903898
UMLS CUI [4]
C0537551
UMLS CUI [5]
C1174780
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;
Descrizione

Insulin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021641
drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and reglan®(metoclopramide);
Descrizione

Pharmaceutical Preparations Affecting Gastrointestinal Motility | Anticholinergic Agents | Macrolide Antibiotics | Dopamine Antagonists | Opioids | Reglan | Metoclopramide

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
UMLS CUI [2]
C0242896
UMLS CUI [3]
C0003240
UMLS CUI [4]
C0242702
UMLS CUI [5]
C0242402
UMLS CUI [6]
C0034977
UMLS CUI [7]
C0025853
systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including advair®) steroids known to have a high rate of systemic absorption;
Descrizione

Systemic steroids Oral | Systemic steroids Intravenous | Systemic steroids Intramuscular | Inhaled steroids | Steroids Intrapulmonary | Advair | Systemic Absorption Rate High

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2825233
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C2825233
UMLS CUI [2,2]
C1522726
UMLS CUI [3,1]
C2825233
UMLS CUI [3,2]
C1556154
UMLS CUI [4]
C2065041
UMLS CUI [5,1]
C0038317
UMLS CUI [5,2]
C1522224
UMLS CUI [6]
C0965130
UMLS CUI [7,1]
C3850076
UMLS CUI [7,2]
C1521828
UMLS CUI [7,3]
C0205250
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00477581

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Metformin
Item
treatment with metformin for at least 2 months
boolean
C0025598 (UMLS CUI [1])
Glycosylated hemoglobin A
Item
has hba1c 7.0% to 11.0%, inclusive, at screening
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi)25 kg/m^2 to 45 kg/m^2, inclusive
boolean
C1305855 (UMLS CUI [1])
Pharmaceutical Preparations Illicit | Therapeutic procedure Stable
Item
list of medications that are not allowed or the patient has been on stable treatment for at least 2 months:
boolean
C0013227 (UMLS CUI [1,1])
C0332266 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Hormone replacement therapy | Gender
Item
hormone replacement therapy (female subjects)
boolean
C0282402 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Gender Oral Contraceptives
Item
oral contraceptives (female subjects)
boolean
C0079399 (UMLS CUI [1,1])
C0009905 (UMLS CUI [1,2])
Antihypertensive Agents
Item
antihypertensive agents
boolean
C0003364 (UMLS CUI [1])
Antilipemic agent
Item
lipid-lowering agents
boolean
C0086440 (UMLS CUI [1])
Thyroid hormone replacement therapy
Item
thyroid replacement therapy
boolean
C2242640 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exenatide | Byetta | Dipeptidyl-Peptidase IV Inhibitors
Item
has been treated with exenatide (byetta®) or any dpp-4 inhibitor prior to screening
boolean
C0167117 (UMLS CUI [1])
C1636686 (UMLS CUI [2])
C1827106 (UMLS CUI [3])
Investigational New Drugs | Study Subject Participation Status
Item
received any study medication or participated in any type of clinical trial within 30 days prior to screening
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Blood Donation | Blood Donation Planned
Item
has donated blood within 60 days of screening visit or is planning to donate blood during the study
boolean
C0005794 (UMLS CUI [1])
C0005794 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Pharmaceutical Preparations
Item
treated with any of the following medications:
boolean
C0013227 (UMLS CUI [1])
Sulfonylurea | Thiazolidinediones
Item
sulfonylurea or thiazolidinedione within 3 months of screening;
boolean
C0038766 (UMLS CUI [1])
C1257987 (UMLS CUI [2])
alpha-Glucosidase Inhibitors | Meglitinide | nateglinide | Pramlintide | Symlin
Item
alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (symlin®)within 30 days of screening;
boolean
C1299007 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0903898 (UMLS CUI [3])
C0537551 (UMLS CUI [4])
C1174780 (UMLS CUI [5])
Insulin
Item
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;
boolean
C0021641 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Gastrointestinal Motility | Anticholinergic Agents | Macrolide Antibiotics | Dopamine Antagonists | Opioids | Reglan | Metoclopramide
Item
drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and reglan®(metoclopramide);
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
C0242896 (UMLS CUI [2])
C0003240 (UMLS CUI [3])
C0242702 (UMLS CUI [4])
C0242402 (UMLS CUI [5])
C0034977 (UMLS CUI [6])
C0025853 (UMLS CUI [7])
Systemic steroids Oral | Systemic steroids Intravenous | Systemic steroids Intramuscular | Inhaled steroids | Steroids Intrapulmonary | Advair | Systemic Absorption Rate High
Item
systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including advair®) steroids known to have a high rate of systemic absorption;
boolean
C2825233 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C2825233 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C2825233 (UMLS CUI [3,1])
C1556154 (UMLS CUI [3,2])
C2065041 (UMLS CUI [4])
C0038317 (UMLS CUI [5,1])
C1522224 (UMLS CUI [5,2])
C0965130 (UMLS CUI [6])
C3850076 (UMLS CUI [7,1])
C1521828 (UMLS CUI [7,2])
C0205250 (UMLS CUI [7,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial